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HRS Meeting will take place in Denver, 8-11/5/13  
 
EuroPCR to be held in Paris, 21-24/5/13  
 
EuroPace will be held in Athens, 23-26/6/13  
 
ESC Congress will be held in Amsterdam, 31/8-4/9/13 
 
TCT Meeting: San Francisco, 28/10-1/11/13  
 
AHA 2013: Dallas, 16-20/11/13   
  
Pre-RELAX-AHF and RELAX-AHF Trials: Relaxin 
Reduces 6-month Mortality in Acute Heart Failure 
Patients 
 
In the Pre-RELAX-AHF (Relaxin in Acute Heart 
Failure) phase II study and RELAX-AHF phase III study 
patients hospitalized for acute heart failure were 
randomized within 16 h to IV placebo or serelaxin. 
Serelaxin reduced 6-month mortality in both studies 
(combined studies: N = 1,395; hazard ratio: 0.62; p = 
0.0076). In RELAX-AHF, serelaxin improved the 
markers of cardiac (high-sensitivity cardiac troponin T), 
renal (creatinine/cystatin-C), and hepatic (AST/ALT) 
damage and of decongestion (N-T pro–BNP), while 
changes in these markers at day 2 and worsening heart 
failure during admission were associated with 6-month 
mortality. The authors concluded that early 
administration of serelaxin was associated with a 
reduction of 6-month mortality, while fewer signs of 
organ damage and more rapid relief of congestion were 
noted during the first days after admission (Metra et al, J 
Am Coll Cardiol 2013;61:196–206) 
 
Favorable 5-Year Outcome after TAVI 
 
The 5-year outcome was evaluated in 88 patients 
undergoing successful TAVI with a balloon-expandable 
valve. Mean aortic valve gradient decreased from 46 + 18 
mm Hg to 10 + 4.5 mm Hg after TAVI and maintained at 
11.8 + 5.7 mm Hg at 5 years (p for post-TAVI trend = 
0.06). Mean aortic valve area increased from 0.62 + 0.17 
cm2 to 1.67 + 0.41 cm2 after TAVI and 1.40 + 0.25 cm2 at 
5 years (p for post-TAVI trend <0.01). At 5 years, 3 
patients (3.4%) had moderate prosthetic valve 
dysfunction. Survival rates at 1 to 5 years were 83%, 
74%, 53%, 42%, and 35%, respectively. Median survival 
time after TAVI was 3.4 years, and the risk of death was 
significantly increased in patients with chronic 
obstructive pulmonary disease (hazard ratio [HR]: 2.17) 
and at least moderate paravalvular regurgitation (adjusted 
HR: 2.98). Thus, a favorable long-term outcome after 
TAVI was demonstrated. Signs of moderate prosthetic 
valve failure were observed in 3.4% of patients. No 
patients developed severe prosthetic regurgitation or 
stenosis. Comorbidities, mainly chronic lung disease and 
at least moderate paravalvular regurgitation, were 
associated with reduced long-term survival (Toggweiler 
et al, J Am Coll Cardiol 2013;61:413–419).  
 
MADIT-CRT: Patients With Better Ejection Fraction 
Benefit the Most from Cardiac Resynchronization 
 
 In the MADIT-CRT study, among 1,809 patients, 
there were 696 (38%) patients with LVEF >30% (in the 
range of 30.1% to 45.3%); 914 patients (50.5%) with 
LVEF 26% to 30%; and 199 patients with LVEF <25% 
(11%). The mean reduction in LV end-diastolic volume 
with CRT-D therapy at the 1-year follow-up was directly 
related to increasing LVEF (LVEF >30%: 22.3%; LVEF 
26% to 30%: 20.1%; and LVEF <25%: 18.7% reduction, 
respectively [p = 0.001]). CRT-D treatment similarly 
reduced the risk of HF/death in patients with LVEF >30% 
(hazard ratio [HR]: = 0.56, p = 0.003), LVEF 26% to 
30% (HR: 0.67, p = 0.007), and LVEF <25% (HR: 0.57, 
p = 0.03; all p values for LVEF-by-treatment interactions 
>0.1). The authors concluded that the clinical benefit of 
CRT was evident regardless of baseline LVEF, including 
those with LVEF >30%, whereas the echocardiographic 
response was increased with increasing LVEF, indicating 
that patients with better LVEF benefit the most (Kutyifa 
V et al, J Am Coll Cardiol 2013;61:936–944). 
 
LBBB-Induced Cardiomyopathy Resolved with CRT 
 
Among 375 candidates for CRT, 6 patients (1.6%) 
were identified who met all the following criteria for 
LBBB-induced cardiomyopathy: 1) history of typical 
LBBB for >5 years; 2) LV ejection fraction (EF) >50%; 
3) decrease in LVEF to <40% and development of heart 
failure (HF) to NYHA functional class II to IV over 
several years; 4) major mechanical dyssynchrony; 5) no 
known etiology of cardiomyopathy; and 6) super-
response to CRT with LVEF >45% and decrease in 
NYHA functional class at 1 year. Heart failure in these 
patients developed over a mean of 11.6 years. At the time 
of referral, Doppler echocardiograms showed major 
mechanical dyssynchrony. During CRT, NYHA 
functional class decreased, LV dimensions normalized 
and mechanical dyssynchrony was nearly resolved in all 
patients, and mean LVEF increased from 31 + 12% to 56 
+ 8% (p = 0.027). The authors concluded that these 
observations support the existence of a specific LBBB-
induced cardiomyopathy resolved by CRT (Vaillant C et 




Dual Gene Therapy Provides Highly Efficient 
Biological Pacing 
Dual gene therapy to effect biological pacing was 
tested by implanting either hyperpolarization-activated 
cyclic nucleotide–gated (HCN) channel 2 (HCN2), or the 
skeletal muscle sodium channel 1 (SkM1), or both with 
the appropriate adenovirus construct into the left bundle 
branches (LBB) or left ventricular (LV) epicardium of 
AV-blocked dogs. During stable peak gene expression on 
days 5 to 7, HCN2/SkM1 LBB-injected dogs showed 
highly stable in vivo pacemaker activity superior to SkM1 
or HCN2 alone and superior to LV-implanted dogs with 
regard to beating rates (resting ~80 bpm; max ~130 bpm), 
no dependence on electronic backup pacing, and 
enhanced modulation of pacemaker function during 
circadian rhythm or epinephrine infusion. In vitro isolated 
LV of dogs overexpressing SkM1 manifested a more 
negative action potential (AP) threshold. The authors 
concluded that LBB-injected HCN2/SkM1 potentially 
provides a more clinically suitable biological pacemaker 
strategy than other reported constructs, attributable to the 
more negative AP threshold and injection into the LBB 
(Boink GJJ et al, J Am Coll Cardiol 2013;61:1192–201).  
 
Better Long-Term Outcome With Chest Compression 
Alone CPR  
A retrospective cohort study combined 2 randomized 
trials comparing the short-term survival effects of CPR 
with chest compression alone or chest compression plus 
rescue breathing. Of the 2496 subjects, 1243 (50%) were 
randomly assigned to chest compression alone and 1253 
(50%) to chest compression plus rescue breathing. 
Baseline characteristics were similar in the 2 groups. 
During the 1153.2 person-years of follow-up, there were 
2260 deaths and 236 long-term survivors. Randomization 
to chest compression alone in comparison with chest 
compression plus rescue breathing was associated with a 
lower risk of death after adjustment for potential 
confounders (hazard ratio, 0.91; P=0.02). The authors 
concluded that there is long-term mortality benefit of 
dispatcher CPR instruction strategy consisting of chest 
compression alone rather than chest compression plus 
rescue breathing among adult patients with cardiac arrest 
(Dumas F et al, Circulation 2013;127:435-441). 
 
Permanent Cardiac Pacing in Children: LV Apical 
and LV Lateral Wall Pacing are Associated With the 
Best Preservation of LV Function 
Children (N=178; aged <18 years, median age 11.2 
years) from 21 centers with AV block and no structural 
heart disease undergoing permanent pacing were 
followed up for a median of 5.4 years. Pacing sites were 
the free wall of the right ventricular (RV) outflow tract 
(n=8), lateral RV (n=44), RV apex (n=61), RV septum 
(n=29), left ventricular (LV) apex (n=12), LV midlateral 
wall (n=17), and LV base (n=7). LV synchrony, pump 
function, and contraction efficiency were better in 
children paced at the LV apex/LV midlateral wall. LV 
dyssynchrony correlated inversely with LV ejection 
fraction (EF) (R=0.80, P=0.031). Pacing from the RV 
outflow tract/lateral RV predicted significantly decreased 
LV function (LVEF <45%; odds ratio-OR, 10.72; 
P=0.005), whereas LV apex/LV midlateral wall pacing 
was associated with preserved LV function (LVEF ≥55%; 
OR, 8.26; P=0.018). The authors concluded that the site 
of ventricular pacing has a major impact on LV 
mechanical synchrony, efficiency, and pump function in 
children who require lifelong pacing. LV apex/LV 
midlateral wall pacing has the greatest potential to 
prevent pacing-induced LV dysfunction (Janousek J et al, 
Circulation 2013;127:613-623).  
 
Infection Remains a Problem for Ventricular Assist 
Devices (VADs) Despite Use of Newer, Smaller 
Devices 
Among 150 patients who received a VAD (2006–
2008) at 11 US cardiac centers (86 or 57% receiving 
HeartMate II), 33 (22%) developed 34 device infections 
with an incidence rate of 0.10 per 100 person-days. The 
median time to infection was 68 days. The driveline was 
the most frequently infected site (n=28); 18 (64%) were 
associated with invasive disease. Staphylococci were the 
most common bacteria (47%); pseudomonas or other 
Gram-negative bacteria caused 32% of infections. A 
history of depression and elevated baseline serum 
creatinine were independent predictors of VAD infection 
(hazard ratio-HR=2.8; P=0.007 and 1.7; P=0.023, 
respectively). HeartMate II was also associated with an 
increased risk of infection. VAD infection increased 1-
year mortality (HR=5.6; P<0.0001). The authors 
concluded that infection frequently complicates VADs 
which adversely affects survival, and remains a problem 
despite the use of newer, smaller devices. Depression and 
renal dysfunction may increase the risk of VAD infection 
(Gordon RJ et al, Circulation 2013;127:691-702).  
 
PROTECT AF Trial: Left Atrial Appendage (LAA) 
Closure is Noninferior to Anticoagulation  
Patients (n=707) with nonvalvular atrial fibrillation 
and at least 1 risk factor were randomized to the 
Watchman LAA closure device (n=463) or continued 
warfarin (n=244) in a 2:1 ratio. Post-procedurally, 
warfarin was continued for ~45 days, followed by 
clopidogrel for 4.5 months and lifelong aspirin. Study 
discontinuation rates were 15.3% (71/463) and 22.5% 
(55/244) for the Watchman and warfarin groups, 
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respectively. The time in therapeutic range for the 
warfarin group was 66%. After a mean follow-up of 2.3 
years, the primary efficacy event (stroke, systemic 
embolism, and cardiovascular death) rates were 3.0% and 
4.3% in the Watchman and warfarin groups, respectively 
(relative risk, 0.71 per year), which met the criteria for 
noninferiority. There were more primary safety events in 
the Watchman group (5.5% per year) than in the control 
group (3.6% per year; relative risk, 1.53). The authors 
concluded that left atrial appendage closure is noninferior 
to anticoagulation with warfarin (Reddy VY et al, 
Circulation 2013;127:720-729).  
 
FREEDOM Trial: CABG is More Cost-effective Than 
DES PCI for Patients with Diabetes and Multivessel 
Coronary Artery Disease (CAD)  
A total of 1900 patients with diabetes and multivessel 
CAD were randomized to PCI with DES (DES-PCI; 
n=953) or CABG (n=947) (2005-2010). Although initial 
procedural costs were lower for CABG, total costs for the 
index hospitalization were $8622 higher per patient. Over 
5 years, follow-up costs were higher with PCI, owing to 
more frequent repeat revascularization and higher 
outpatient medication costs. However, cumulative 5-year 
costs remained $3641 higher per patient with CABG. 
There were only modest gains in survival with CABG, 
but when the results were projected to lifetime, CABG 
appeared economically attractive relative to DES-PCI, 
with substantial gains in both life expectancy and quality-
adjusted life expectancy. The authors concluded that 
CABG, despite higher initial costs, is a cost-effective 
revascularization strategy compared with DES-PCI for 
patients with diabetes and multivessel CAD (Magnuson 
EA et al, Circulation, 2013;127:820-831).  
 
LESSER EARTH Trial: CRT in Patients with Narrow 
QRS (<120 ms) Offers no Improvement and May be 
Harmful  
The LESSER-EARTH trial, comparing the effects of 
cardiac resynchronization therapy (CRT) in patients with 
severe LV dysfunction and a QRS duration <120 ms, was 
interrupted prematurely by the Data Safety and 
Monitoring Board because of futility and safety concerns 
after 85 patients were randomized. Changes in exercise 
duration after 12 months were no different in patients 
with and without active CRT. Similarly, no significant 
differences were observed in LV endsystolic volumes and 
ejection fraction. CRT was rather associated with a 
significant reduction in the 6-minute walk distance, an 
increase in QRS duration and a nonsignificant trend 
toward an increase in heart failure–related 
hospitalizations (15 hospitalizations in 5 patients vs 4 in 4 
patients). The authors concluded that in patients with 
heart failure and an ejection fraction ≤35%, and a QRS 
duration <120 ms, CRT did not improve clinical 
outcomes and was even associated with potential harm 
(Thibault B et al, Circulation 2013; 127:873-881.)  
 
Endovascular Reperfusion Therapy for Stroke: The 
Importance of Time From Initial CT to Groin 
Puncture (“Picture-to-Puncture” Time)  
For acute stroke management, guidelines advocate the 
initiation of thrombolysis (IV tPA) within 60 minutes of 
patient arrival. However, <5% of all stroke patients 
receive tPA and <26.6% of tPA patients achieve this goal. 
The advent of endovascular reperfusion therapies has 
broadened the time window for treatment to 8 hours, 
rendering it possible to treat patients with larger clot 
burdens who do not qualify for tPA or patients in whom 
tPA has failed. A retrospective study evaluated 193 
patients treated with endovascular therapy (2010 – 2012) 
at a single center. Patients transferred from outside 
hospitals were compared with locally treated patients. 
Good outcomes, as defined by 90-day modified Rankin 
Scale scores of 0 to 2, were analyzed by transfer status as 
well as time from initial CT to groin puncture (“picture-
to-puncture” time). Outside transfers had longer picture-
to-puncture times (205 min vs 89 min; P<0.001). This 
yielded fewer patients with favorable Alberta Stroke 
Program Early CT Scores on preprocedural CT imaging 
(Alberta Stroke Program Early CT Scores >7: 50% vs 
76%; P<0.001) and significantly worse clinical outcomes 
(29% vs 51%; P=0.003). Picture-to-puncture times were 
independently associated with good outcomes (odds ratio, 
0.994; P=0.009). The authors concluded that delays in 
picture-to-puncture times for interhospital transfers 
reduce the probability of good outcomes among stroke 
patients undergoing endovascular therapy (Sun CJ et al, 
Circulation 2013;127:1139-1148.) 
 
IMS III Study: A Combined Approach of 
Thrombolysis and Endovascular Therapy for Stroke 
is no Better than Thrombolysis 
Patients with acute ischemic stroke who had received 
intravenous (IV) t-PA within 3 hours after symptom onset 
were randomly assigned to receive additional 
endovascular therapy (n=434) or IV t-PA alone (n=222), 
in a 2:1 ratio. The study was stopped early because of 
futility after 656 participants had undergone 
randomization. The proportion of participants with a 
modified Rankin score of <2 at 90 days did not differ 
significantly according to treatment (40.8% with 
endovascular therapy and 38.7% with IV t-PA). Findings 
in the endovascular-therapy and IV t-PA groups were 
similar for mortality at 90 days (19.1% and 21.6%, 
respectively; P=NS) and number of patients with 
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symptomatic intracerebral hemorrhage within 30 hours 
after initiation of t-PA (6.2% and 5.9%, respectively; 
P=NS). The authors concluded the similar safety 
outcomes and no significant difference in functional 
independence were observed with endovascular therapy 
after t-PA, as compared with t-PA alone (Broderick JP et 
al, N Engl J Med 2013;368:893-903). 
 
SYNTHESIS Expansion Study: Endovascular 
Therapy for Stroke is not Superior to Thrombolysis 
Patients (N=362) with acute ischemic stroke were 
randomly assigned, within 4.5 hours after onset, to 
endovascular therapy (intraarterial thrombolysis with t-
PA, mechanical clot disruption or retrieval, or a 
combination) (n=181) or IV t-PA (n=181); therapies were 
effected within a median time of 3.75 h and 2.75 h, 
respectively (P<0.001). The primary outcome was 
survival free of disability at 3 months. At 3 months, 55 
patients in the endovascular-therapy group (30.4%) and 
63 in the t-PA group (34.8%) were alive without 
disability (odds ratio, 0.71; P=NS). Intracranial 
hemorrhage within 7 days occurred in 6% of the patients 
in each group, and there were no significant differences 
between groups in the rates of other serious adverse 
events or mortality. The authors concluded that in 
patients with acute ischemic stroke, endovascular therapy 
is not superior to standard treatment with IV t-PA 
(Ciccone A et al, N Engl J Med 2013;368:904-913). 
 
Rekindled Interest in Pacemaker Reuse as a Feasible, 
Safe and Viable Option  
Among 603 consecutive patients receiving a 
permanent pacemaker (2000–2010), 307 patients received 
resterilized pacemakers, and 296 control patients a new 
pacemaker. A total of 85 pacemakers had to be explanted, 
31 in the control group (10.5%) and 54 in the study group 
(17.6%; relative risk-RR, 1.68; P=0.02). The primary 
end-point (unexpected battery depletion/ infection/ device 
dysfunction) was reached by 43 patients, 16 in the control 
group (5.5%) and 27 in the study group (7.2%; RR, 1.3; 
P=0.794). In terms of individual outcomes, 5 new 
pacemakers (1.7%) and 11 resterilized pacemakers 
(3.6%) had unexpected battery depletion (RR, 2.12; 
P=0.116); 3.7% new pacemakers and 3.2% reused 
pacemakers had a procedure-related infection (RR, 0.87; 
P=0.46); and 1 pacemaker in the study group 
malfunctioned. The authors concluded that pacemaker 
reuse is feasible and safe and is a viable option for patient 
with bradyarrhythmias. Other than an expected shorter 
pulse generator life, pacemaker reuse is not inferior to use 
of new devices (Nava S et al, Circulation 
2013;127:1177-1183.)  
Persistent LBBB post TAVI is Associated With More 
Pacemaker Implants but no Worse Clinical Outcome  
Among 1060 patients undergoing transcatheter aortic 
valve implantation (TAVI) with a CoreValve System 
(2007-2011), 818 patients (77%) without LBBB or 
pacemaker at admission or having a pacer implant within 
48 h were analyzed. Among them, 224 patients (group A; 
27.4%) developed a persistent LBBB vs 594 (group B; 
72.6%) who did not. A low implantation of the valve was 
significantly more frequent in group A (15% vs 9.8%, 
P=0.02). During median follow-up of 438 days, LBBB 
was not associated with higher all-cause or cardiac 
mortality, or hospitalization for heart failure at 30 days or 
1 year. At 30 days, but not at 1 year, group A had a 
significantly higher rate of pacemaker implantation. The 
authors concluded that persistent LBBB after CoreValve 
implantation showed no effect on hard end points, but led 
to a higher short-term rate of pacemaker implantation 
(Testa L et al, Circulation 2013;127:1300-1307). 
 
PC Trial: PFO Closure for Cryptogenic Stroke not 
Superior to Medical Therapy per the Intention-to-
Treat Analysis 
In a multicenter trial, patients with a patent foramen 
ovale (PFO) and ischemic stroke, transient ischemic 
attack (TIA), or a peripheral thromboembolic event were 
randomly assigned to undergo closure of the PFO with 
the Amplatzer PFO Occluder or to receive medical 
therapy. At a mean follow-up of ~4 years, the primary 
end point (death, nonfatal stroke, TIA, or peripheral 
embolism) occurred in 7 of 204 patients (3.4%) in the 
closure group and in 11 of 210 patients (5.2%) in the 
medical-therapy group (hazard ratio-HR for closure vs. 
medical therapy, 0.63; P=NS). Nonfatal stroke occurred 
in 1 patient (0.5%) in the closure group and 5 patients 
(2.4%) in the medical-therapy group (HR, 0.20; P=NS), 
and TIA occurred in 5 (2.5%) and 7 patients (3.3%), 
respectively (HR, 0.71; P=NS). The authors concluded 
that according with an analysis performed on data for the 
intention-to-treat population, PFO closure for secondary 
prevention of cryptogenic embolism did not result in a 
significant reduction in the risk of recurrent embolic 
events or death as compared with medical therapy (Meier 
B et al, N Engl J Med 2013;368:1083-1091). 
 
RESPECT Trial: PFO Closure Superior to Medical 
Therapy in the Per-Protocol and As-Treated 
Analyses, but not in Intention-To-Treat Analysis 
A prospective, multicenter trial randomly assigned 
980 patients (mean age, 45.9 years) with cryptogenic 
stroke, in a 1:1 ratio, to medical therapy alone or closure 
of the patent foramen ovale (PFO). The medical-therapy 
group received one or more antiplatelet medications 
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(74.8%) or warfarin (25.2%). Follow-up was unequal in 
the 2 groups (1375 patient-years in the closure group vs. 
1184 in the medical group, P=0.009) due to a higher 
dropout rate in the medical group. In the intention-to-treat 
cohort, 9 patients in the closure group and 16 in the 
medical group had a recurrence of stroke (hazard ratio-
HR with closure, 0.49; P=0.08). The difference in the rate 
of recurrent stroke was significant in the prespecified per-
protocol cohort (6 events in the closure group vs. 14 
events in the medical group; HR, 0.37; P=0.03) and in the 
as-treated cohort (5 events vs. 16 events; HR, 0.27; 
P=0.007). Serious adverse events were similar, 23% in 
the closure group vs 21.6% in the medical-therapy group 
(P=NS). Procedure-related or device-related serious 
adverse events occurred in 21 of 499 patients in the 
closure group (4.2%), but the rate of atrial fibrillation or 
device thrombus was not increased. The authors 
concluded that in the primary intention-to-treat analysis, 
there was no significant benefit associated with closure of 
a PFO in patients with a cryptogenic ischemic stroke. 
However, closure was superior to medical therapy alone 
in the prespecified per-protocol and as-treated analyses, 
with a low rate of associated risks (Carroll JD et al, N 
Engl J Med 2013;368:1092-1100). 
 
RED-HF Trial: No Benefit of Anemia Treatment With 
Darbepoetin in Patients With Systolic Heart Failure 
In a randomized, double-blind trial, 2278 patients with 
systolic heart failure and mild-to-moderate anemia 
(hemoglobin, 9-12 g/dL) were assigned to receive either 
darbepoetin alfa (to achieve a hemoglobin target of 13 
g/dL) or placebo. The primary outcome (death from any 
cause or hospitalization for worsening heart failure) 
occurred in 576 of 1136 patients (50.7%) in the 
darbepoetin group and 565 of 1142 patients (49.5%) in 
the placebo group (hazard ratio in the darbepoetin group, 
1.01; P=NS). The neutral effect of darbepoetin alfa was 
consistent across all prespecified subgroups. Stroke 
occurred in 42 patients (3.7%) in the darbepoetin group 
and 31 patients (2.7%) in the placebo group (P=NS). 
Thromboembolic adverse events were noted in 153 
patients (13.5%) in the darbepoetin group and 114 
patients (10.0%) in the placebo group (P=0.01). Cancer-
related adverse events were similar in the two groups. 
The authors concluded that darbepoetin alfa did not 
improve clinical outcomes in patients with systolic heart 
failure and mild-to-moderate anemia (Swedberg K et al, 
N Engl J Med 2013; 368:1210-1219).  
 
AF Confers a Higher Risk for Cognitive Decline and 
Dementia, Regardless of Prior History of Stroke 
A metaanalysis of 21 studies indicated that atrial 
fibrillation (AF) was associated with a higher risk for 
cognitive decline in patients with first or recurrent stroke 
(relative risk - RR, 2.70) and in a broader population 
including patients with or without a history of stroke (RR, 
1.40). Analysis of prospective studies alone yielded 
similar results (RR, 1.36), and likewise the analysis of 
dementia which eliminated heterogeneity (RR, 1.38). The 
authors concluded that AF is associated with a higher risk 
for cognitive impairment and dementia, with or without a 
history of clinical stroke (Kalantarian S et al, Ann Intern 
Med 2013;158:338-346). 
 
Important Review and Other Articles  
 
Pathogenesis of acute coronary syndromes (Crea F & 
Liuzzo G, J Am Coll Cardiol 2013; 61:1-11), 2012 
ACCF/AHA/HRS Focused Update for Device-Based 
Therapy of Cardiac Rhythm Abnormalities (Tracy CM et 
al, J Am Coll Cardiol 2013; 61:e6-e75), 2013 
ACCF/AHA Guideline for the management of STEMI 
(O’Gara PT et al, J Am Coll Cardiol 2013; 61:485-510 & 
Circulation 2013;127:e362-e425), Inappropriate sinus 
tachycardia (Olshansky B & Sullivan RM, J Am Coll 
Cardiol 2013; 61:793-801), Sudden cardiac death in 
young athletes (Chandra N et al, J Am Coll Cardiol 2013; 
61:1027-1040), Paravalvular leak after TAVI (Genereux 
P et al, J Am Coll Cardiol 2013; 61:1125-1136), Patient 
selection for ventricular assist devices (Miller LW & 
Guglin M, J Am Coll Cardiol 2013; 61:1125-1136), 
ACCF/HRS/AHA/ASE/HFSA/ SCAI/SCCT/SCMR 2013 
Appropriate Use Criteria for ICDs & CRT (Russo AM, J 
Am Coll Cardiol 2013;61:1318-1368), Update on 
channelopathies (Webster G & Berul CI, Circulation 
2013;127:126-140 ), Heart Disease & Stroke Statistics 
(AHA) (Go AS et al, Circulation 2013;127:e6-e245), 
Therapeutic hypothermia after cardiac arrest (Scirica BM, 
Circulation 2013;127:244-250), Childhood obesity (Li JS 
et al, Circulation 2013;127:260-267), Cost of ventricular 
assist devices (Miller LW et al, Circulation 
2013;127:743-748), Wearable cardioverter-defibrillators 
(Adler A et al, Circulation 2013;127:854-860), Syncope 
(Saklani P et al, Circulation 2013; 127:1330-1339), 
Familial hypercholesterolemia (Hovingh GK et al, Eur 
Heart J 2013;34:962-971), DES (Stefanini GG & Holmes 
DR, N Engl J Med 2013;368:254-265), Adverse effects 
in TAVI (Khatri PJ et al, Ann Intern Med 2013;158:35-
46), Heart failure with preserved ejection fraction (Meyer 
T et al, Ann Intern Med 2013;158:ITC1-1), 
Cardioprotection (Heusch G, Lancet 2013;381(9861): 
166-175), Hypertrophic cardiomyopathy (Maron BJ & 
Maron MS, Lancet 2013;381(9862):242-255)  
 
